- February 15, 2001. Press release.
Merck releases Financial Guidance for 2001. Includes projected sales figures for
certain drugs, and projected expenditures for marketing and research and development.
- January 23, 2001. Press Release
Merck's Earnings Per Share Increased 18% for 2000, Driven By the Strong Momentum
of Five Key Products Contains aggregate sales and income figures, as well as
information on a few specific drugs.
-
Notice of 2000 Annual Meeting and Proxy Statement. Contains exececutive compensation figures,
including salaries and stock options.
- March 22, 2000
SEC 10-K Annual Financial Filing. Contains sales figures and patent expiration dates for
the company's ten largest selling drugs, firm-level R&D figures, information on lawsuits filed
against the firm, income and cost data, stock information, financial holdings, and a complete
list of Merck's subsidiaries (1999 data).
-
Chairman, CEO, President Raymond V. Gilmartin's salary and stock options from the
AFL-CIO's Executive Paywatch database.
|
Political Donations and Lobbying, USA |
|
Drugs Related to IPR Disputes |
- Coumadin (Warfarin)
Until 1998, this drug was marketed by DuPont Merck Pharmaceuticals, a joint venture of the two
larger parent companies (DuPont has since bought out Merck's share). DuPont Merck
lobbied to keep the generic off the market after the patent expired. Also, a lawsuit
resulted from DuPont Merck's assertion that the generic, as prepared by Barr Laboratories,
was a health risk for those taking it.
- October 8, 2002. Joint press release with Jimmy Carter.
Former U.S. President Carter, Merck Chairman Raymond V. Gilmartin Present
Model For Addressing Global Public-Health Challenges. Centers
around Merck's donation program for its drug that fights
onchocerciasis (river blindness).
- Partnerships for Tommorow.
Merck's corporate philathropy report.
- Merck's offer to drop prices for HIV drugs in Developing Countries
On March 7, 2001. Merck offered to sell Crixivan for $600 per patient
per year and Stocrin for $500 per patient per year. Merck oriiginally claimed
that, unlike the price reductions
offered by multinational pharmaceutical firms last year (including Merck)
through the Accelerating Access Initiative, this lower price is available
immediately. However, that afternoon Merck made it clear that it would not
offer the lower prices to all poor countries, and that the deal would
need to be worked out on a country-by-country basis.
In October 2002, Merck annouced further cuts in the price for
Stocrin from the (already reduced) price of $1.37 per patient
per day to $0.95 per patient per day in the poorest, hardest-hit
countries. The price for middle-development countries with
less than 1% HIV prevalence will be $2.10 per patient per day,
down from $2.52.
Merck & Co., Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ
08889-0100
Main number: 908-423-1000
Investor relations 908-423-5881
Washington Office
601 Pennsylvania Ave., NW #1200-N
Washington, DC 20004
(tel) 202-638-4170
(fax) 202-638-3670
Teel Oliver, VP Government Relations